Jump to content

TCMVET Baituxiao Dog Cancer Treatment: Managing Side Effects: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

3 April 2026

  • curprev 18:0018:00, 3 April 2026 ChasMattingly talk contribs 5,729 bytes +5,729 Created page with "Immunohistochemical data have demonstrated augmented inflammatory responses in the immunocompetent syngeneic models uncovered to IL-12-expressing oHSV, suggesting that induction of a systemic immune response might at least partially account for anti-tumor responses . HSV M032 is a genetically modified oncolytic type 1 herpes simplex virus that expresses human IL-12, a T-cell activating cytokine, eliciting a potent immune-related inflammatory response [52, 53]. Sort 1 her..."
Retrieved from "https://whdc.ac/index.php/TCMVET_Baituxiao_Dog_Cancer_Treatment:_Managing_Side_Effects"